White Cover & Massage Effects on Bilirubin and Phototherapy in ABO-Incompatible Newborns

NCT ID: NCT06921330

Last Updated: 2026-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2026-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to examine the effect of white cover and massage application on bilirubin levels and phototherapy duration in newborns with ABO incompatibility receiving phototherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hyperbilirubinemia is a common problem seen in the neonatal period characterized by yellow staining of the skin and sclera, causing an increase in total serum bilirubin \>5 mg/dl. Neonatal jaundice is observed in 60% of term newborns and 80% of preterm newborns. Hyperbilirubinemia is usually physiologic and disappears within a few days. If jaundice becomes severe and pathologic hyperbilirubinemia occurs, it can lead to kernicterus (bilirubin accumulation in parts of the brain) or death.Therefore, any infant with hyperbilirubinemia with elevated serum bilirubin levels requires serious attention and treatment.

ABO incompatibility is a cause of indirect hyperbilirubinemia leading to pathologic jaundice. Newborns with ABO incompatibility tend to have higher bilirubin levels due to impaired bilirubin excretion during the neonatal period. ABO incompatibility is observed in approximately 25% of mother-infant pairs. ABO incompatibility may develop when the mother's blood type is O and the baby's blood type is A or B. In ABO incompatibility, maternal anti-A or anti-B antibodies cross the placenta and bind to A/B antigens on the surface of fetal erythrocytes. Antibody-coated erythrocytes are destroyed in the reticuloendothelial system. Bilirubin increases as a result of heme catabolism that is released with the destruction of erythrocytes, and this is reflected in the clinic as neonatal jaundice. In the presence of ABO incompatibility, early screening and close follow-up of newborns in terms of development of hyperbilirubinemia is very important. Traditional treatment modalities for jaundice due to ABO incompatibility are phototherapy and exchange transfusion.

The primary treatment of neonatal jaundice is phototherapy. The efficacy of phototherapy depends on the phototherapy light source, light intensity, the distance between the phototherapy light and the newborn, and the body surface area exposed to light. Phototherapy has potential side effects such as hyperthermia, dehydration, diarrhea, bronze baby syndrome and skin burns in newborns. Therefore, the use of phototherapy should be minimized and solutions should be found to shorten the duration of phototherapy. To increase the effectiveness of phototherapy treatment, a reflective material can be added to the phototherapy. White fabric that can be used as a reflector can reflect the scattered phototherapy light. When fabrics made of reflective materials are hung on the phototherapy device, they can capture light that may be scattered from the baby to the environment and reflect the light back to the baby. The white fabric can increase the irradiance and thus increase bilirubin conversion. Bilirubin is excreted from the body through feces. Removal of bilirubin from the body reduces jaundice. Massage decreases bilirubin levels by increasing the frequency of bowel movements in newborn babies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Newborn Jaundice Hyperbilirubinemia, Neonatal ABO Incompatibility Newborn Massage Phototherapy White Cover

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

1. During phototherapy, the phototherapy devices of term newborns with abo incompatibility will be covered with white cover.
2. During phototherapy, infant massage including facial massage, chest massage, arm massage, abdominal massage and leg massage will be applied to term newborns twice a day for 15 minutes each session with an interval of 6 hours.

Group Type EXPERIMENTAL

white cover-newborn massage

Intervention Type OTHER

A white cover will be covered over the incubator during phototherapy. Baby massage will be applied during phototherapy.

control group

The hospital's clinical routine will be applied to the newborns in the control group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

white cover-newborn massage

A white cover will be covered over the incubator during phototherapy. Baby massage will be applied during phototherapy.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

white cover and massage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Abo-Incompatibility term babies with a gestational age between 37-42 weeks,
* Does not have a respiratory, cardiovascular, gastrointestinal or neurological disorder or syndrome that would prevent or complicate oral feeding,
* Birth weight of 2500 g and above,
* With phototherapy indication,
* Do not have any health problems other than neonatal jaundice detected in the prenatal period,
* Those with a stable health condition,
* Orally fed,
* No clinical signs of dehydration,
* Do not have any skin problems that would prevent baby massage,
* Newborns with written and verbal informed consent from their families will be included in the study.

Exclusion Criteria

* Premature,
* Those with congenital malformations,
* Those with hyperbilirubinemia requiring exchange transfusion,
* Those with Rh hemolytic disease,
* Having a positive culture test (sepsis),
* Those with glucose-6-phosphate dehydrogenase (G6PD) deficiency,
* Birth weight below 2500 grams,
* Those who were referred to another center during the research,
* Discharged early,
* Unexpected complications developed during the research,
* Bronze child syndrome occurs during phototherapy,
* Newborns who develop a pathology that will prevent or complicate oral feeding will not be included in the study.
Minimum Eligible Age

12 Hours

Maximum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karabuk University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zeynep ÇİFTCİ DEMİRTAŞ

Midwife

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zeynep ze ÇİFTCİ DEMİRTAŞ, 1

Role: PRINCIPAL_INVESTIGATOR

midwife

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karabük Eğitim Ve Araştırma Hastanesi

Karabük, Karabük Province, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zeynep ÇİFTCİ DEMİRTAŞ, midwife

Role: CONTACT

+905076339774 ext. +905076339774

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-77192459-050.99-382574

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.